Adrenal gland - CDH17 negative adrenocortical adenoma.
Breast - CDH17 negative invasive lobular breast cancer.
Colon - Colorectal adenocarcinoma with strong CDH17 immunostaining of all tumor cells (CDH17 immunohistochemistry).
Esophagus - Adenocarcinoma showing strong CDH17 immunostaining of tumor cells (CDH17 immunohistochemistry).
Esophagus - CDH17 negative squamous cell carcinoma.
Ileum - Neuroendocrine tumor with strong CDH17 immunostaining of all tumor cells (CDH17 immunohistochemistry).
Kidney - CDH17 negative clear cell carcinoma.
Lung - Adenocarcinoma with variable CDH17 staining of most tumor cells (CDH17 immunohistochemistry).
Lung - CDH17 negative adenocarcinoma.
Lung - CDH17 negative small cell carcinoma.
Lung - Neuroendocrine tumor depicting a strong CDH17 staining of tumor cells (CDH17 immunohistochemistry).
Lung- CDH17 negative neuroendocrine tumor.
Lymph node - CDH17 negative Hodgkin’s lymphoma.
Oral cavity - CDH17 negative squamous cell carcinoma.
Ovary - CDH17 negative serous high-grade carcinoma.
Ovary - Endometroid carcinoma with intense CDH17 immunostaining of tumor cells (CDH17 immunohistochemistry).
Ovary - Mucinous carcinoma with strong CDH17 immunostaining of tumor cells (CDH17 immunohistochemistry).
Pancreas - Adenocarcinoma of the papilla Vaterii with strong CDH17 staining of tumor cells (CDH17 immunohistochemistry).
Pancreas - CDH17 negative ductal adenocarcinoma.
Pancreas - CDH17 negative neuroendocrine tumor.
Pancreas - Neuroendocrine tumor with strong CDH17 staining ofa small fraction of tumor cells (CDH17 immunohistochemistry).
Prostate - Adenocarcinoma (Gleason 4+4=8) with strong CDH17 positivity in 30_ of tumor cells.
Prostate - CDH17 negative adenocarcinoma (Gleason 3+3=6).
Salivary gland - CDH17 negative Warthin tumor.
Soft tissue - CDH17 negative liposarcoma.
Stomach - CDH17 negative gastrointestinal stromal tumor (GIST).
Stomach - Gastric adenocarcinoma (diffuse type) with strong CDH17 staining of tumor cells (CDH17 immunohistochemistry)
Stomach - Gastric adenocarcinoma (intestinal type) exhibiting a strong CDH17 immunostaining of all tumor cells (CDH17 immunohistochemistry).
Testis - CDH17 negative seminoma.
Thyroid - CDH17 negative papillary carcinoma.
Urinary bladder - CDH17 negative muscle-invasive urothelial carcinoma.